Using Triamcinolone and Platelet-Rich Plasma to Treat Joint Pain in Horses
Author Information
Author(s): Guidoni Kübra, Chiaradia Elisabetta, Pepe Marco, Di Meo Antonio, Tognoloni Alessia, Seccaroni Matteo, Beccati Francesca
Primary Institution: University of Perugia
Hypothesis
The use of PRP after a single dose of TA may potentially improve the clinical signs of MCP joint OA longer than injection of TA alone.
Conclusion
Combining PRP with TA could enhance chondrocyte viability and provide a better long-term therapeutic option for treating OA in racehorses.
Supporting Evidence
- Platelet-rich plasma (PRP) protects cartilage cells from the adverse effects of triamcinolone acetonide.
- Horses treated with TA and PRP had better treatment outcomes than those treated with TA alone.
- PRP may improve clinical outcomes by reducing corticosteroid-induced adverse effects on cartilage cells.
- Both treatments showed improved flexion assessments one week after the last treatment.
Takeaway
This study looked at how two treatments for joint pain in horses work together. Using a special blood treatment with a common medicine helped horses feel better for longer.
Methodology
The study included in vitro tests on chondrocytes and an in vivo trial with 32 racehorses, comparing outcomes between those treated with TA alone and those treated with TA followed by PRP.
Potential Biases
Individual responses to treatment may vary, and the timing of PRP administration could influence results.
Limitations
Lack of diagnostic analgesia in some horses and no analysis of synovial samples to assess changes in biomarkers.
Participant Demographics
32 Thoroughbred racehorses aged between 2 and 5 years, with 13 females and 19 intact males.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website